{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:28:51Z","timestamp":1794367731041,"version":"4.9.0"},"publisher-location":"Totowa, NJ","reference-count":137,"publisher":"Humana Press","isbn-type":[{"value":"9781607614159","type":"print"},{"value":"9781607614166","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-1-60761-416-6_6","type":"book-chapter","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T10:31:06Z","timestamp":1258021866000},"page":"95-121","source":"Crossref","is-referenced-by-count":53,"title":["Pharmacogenetics of ATP-Binding Cassette Transporters and Clinical Implications"],"prefix":"10.1007","author":[{"given":"Ingolf","family":"Cascorbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierk","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,5]]},"reference":[{"key":"6_CR1_6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","volume":"71","author":"P Borst","year":"2002","unstructured":"Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537\u2013592","journal-title":"Annu Rev Biochem"},{"key":"6_CR2_6","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1096\/fasebj.3.14.2574119","volume":"3","author":"PF Juranka","year":"1989","unstructured":"Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583\u20132592","journal-title":"FASEB J"},{"key":"6_CR3_6","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","volume":"94","author":"AH Schinkel","year":"1997","unstructured":"Schinkel AH, Mayer U, Wagenaar E et al (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028\u20134033","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR4_6","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.4049\/jimmunol.161.10.5733","volume":"161","author":"CM Panwala","year":"1998","unstructured":"Panwala CM, Jones JC, Viney JL (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161:5733\u20135744","journal-title":"J Immunol"},{"key":"6_CR5_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CPP38069","volume":"38","author":"MF Fromm","year":"2000","unstructured":"Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69\u201374","journal-title":"Int J Clin Pharmacol Ther"},{"key":"6_CR6_6","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1172\/JCI118699","volume":"97","author":"AH Schinkel","year":"1996","unstructured":"Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517\u20132524","journal-title":"J Clin Invest"},{"key":"6_CR7_6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.2042-7158.1996.tb05904.x","volume":"48","author":"T Terao","year":"1996","unstructured":"Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083\u20131089","journal-title":"J Pharm Pharmacol"},{"key":"6_CR8_6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159\u2013168","journal-title":"Clin Pharmacokinet"},{"key":"6_CR9_6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(91)90141-K","volume":"66","author":"PM Chaudhary","year":"1991","unstructured":"Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85\u201394","journal-title":"Cell"},{"key":"6_CR10_6","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.V80.11.2735.bloodjournal80112735","volume":"80","author":"PM Chaudhary","year":"1992","unstructured":"Chaudhary PM, Mechetner EB, Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735\u20132739","journal-title":"Blood"},{"key":"6_CR11_6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1006\/smim.2001.0322","volume":"13","author":"GJ Randolph","year":"2001","unstructured":"Randolph GJ (2001) Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 13:267\u2013274","journal-title":"Semin Immunol"},{"key":"6_CR12_6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0022-3565(25)12089-2","volume":"275","author":"EG Schuetz","year":"1995","unstructured":"Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011\u20131018","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR13_6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1081\/DMR-120026398","volume":"35","author":"GA Kullak-Ublick","year":"2003","unstructured":"Kullak-Ublick GA, Becker MB (2003) Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev 35:305\u2013317","journal-title":"Drug Metab Rev"},{"key":"6_CR14_6","doi-asserted-by":"publisher","first-page":"14581","DOI":"10.1074\/jbc.M010173200","volume":"276","author":"A Geick","year":"2001","unstructured":"Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581\u201314587","journal-title":"J Biol Chem"},{"key":"6_CR15_6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0002-9440(10)64794-3","volume":"157","author":"MF Fromm","year":"2000","unstructured":"Fromm MF, Kauffmann HM, Fritz P et al (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575\u20131580","journal-title":"Am J Pathol"},{"key":"6_CR16_6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI6663","volume":"104","author":"B Greiner","year":"1999","unstructured":"Greiner B, Eichelbaum M, Fritz P et al (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147\u2013153","journal-title":"J Clin Invest"},{"key":"6_CR17_6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","volume":"76","author":"T Giessmann","year":"2004","unstructured":"Giessmann T, May K, Modess C et al (2004) Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192\u2013200","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR18_6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/cp.1999.v66.a101944","volume":"66","author":"A Johne","year":"1999","unstructured":"Johne A, Brockmoller J, Bauer S et al (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John\u2019s wort (Hypericum perforatum). Clin Pharmacol Ther 66:338\u2013345","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR19_6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2165\/00002018-200427110-00003","volume":"27","author":"M Mannel","year":"2004","unstructured":"Mannel M (2004) Drug interactions with St John\u2019s wort: mechanisms and clinical implications. Drug Saf 27:773\u2013797","journal-title":"Drug Saf"},{"key":"6_CR20_6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/bi0268753","volume":"42","author":"RE Watkins","year":"2003","unstructured":"Watkins RE, Maglich JM, Moore LB et al (2003) 2.1 A crystal structure of human PXR in complex with the St. John\u2019s wort compound hyperforin. Biochemistry 42:1430\u20131438","journal-title":"Biochemistry"},{"key":"6_CR21_6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-3565(24)39245-6","volume":"293","author":"C Pauli-Magnus","year":"2000","unstructured":"Pauli-Magnus C, von Richter O, Burk O et al (2000) Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293:376\u2013382","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR22_6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.clpt.6100505","volume":"84","author":"M Ufer","year":"2008","unstructured":"Ufer M, Dilger K, Leschhorn L et al (2008) Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 84:43\u201346","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR23_6","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.050585397","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473\u20133478","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR24_6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1023\/A:1020433422259","volume":"19","author":"M Horinouchi","year":"2002","unstructured":"Horinouchi M, Sakaeda T, Nakamura T et al (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 19:1581\u20131585","journal-title":"Pharm Res"},{"key":"6_CR25_6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189\u2013199","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR26_6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-3565(24)29643-9","volume":"297","author":"M Tanabe","year":"2001","unstructured":"Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137\u20131143","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR27_6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","volume":"11","author":"MM Ameyaw","year":"2001","unstructured":"Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217\u2013221","journal-title":"Pharmacogenetics"},{"key":"6_CR28_6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR29_6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/01.ftd.0000164293.75854.11","volume":"27","author":"SS Lee","year":"2005","unstructured":"Lee SS, Kim SY, Kim WY et al (2005) MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit 27:531\u2013535","journal-title":"Ther Drug Monit"},{"key":"6_CR30_6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(01)05579-9","volume":"358","author":"E Schaeffeler","year":"2001","unstructured":"Schaeffeler E, Eichelbaum M, Brinkmann U et al (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383\u2013384","journal-title":"Lancet"},{"key":"6_CR31_6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00008571-200106000-00003","volume":"11","author":"M Hitzl","year":"2001","unstructured":"Hitzl M, Drescher S, Van der KH et al (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293\u2013298","journal-title":"Pharmacogenetics"},{"key":"6_CR32_6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00228-004-0733-4","volume":"60","author":"SS Brenner","year":"2004","unstructured":"Brenner SS, Klotz U (2004) P-glycoprotein function in the elderly. Eur J Clin Pharmacol 60:97\u2013102","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR33_6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00228-003-0625-z","volume":"59","author":"K Oselin","year":"2003","unstructured":"Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347\u2013350","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR34_6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","volume":"15","author":"D Wang","year":"2005","unstructured":"Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693\u2013704","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR35_6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1135308","volume":"315","author":"C Kimchi-Sarfaty","year":"2007","unstructured":"Kimchi-Sarfaty C, Oh JM, Kim IW et al (2007) A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity. Science 315:525\u2013528","journal-title":"Science"},{"key":"6_CR36_6","first-page":"718","volume":"61","author":"M Schaefer","year":"2005","unstructured":"Schaefer M, Roots I, Gerloff T (2005) In vitro transport characteristics discriminate wildtype MDR1 (ABCB1) from Ala893Ser and Ala893Thr polymorphisms. Eur J Clin Pharmacol 61:718","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR37_6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0076-6879(05)00027-3","volume":"400","author":"T Ishikawa","year":"2005","unstructured":"Ishikawa T, Sakurai A, Kanamori Y et al (2005) High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol 400:485\u2013510","journal-title":"Methods Enzymol"},{"key":"6_CR38_6","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1002\/jps.20743","volume":"95","author":"MH Crouthamel","year":"2006","unstructured":"Crouthamel MH, Wu D, Yang Z, Ho RJ (2006) A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 95:2767\u20132777","journal-title":"J Pharm Sci"},{"key":"6_CR39_6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1067\/mcp.2002.127739","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572\u2013583","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR40_6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1067\/mcp.2002.126177","volume":"72","author":"Y Kurata","year":"2002","unstructured":"Kurata Y, Ieiri I, Kimura M et al (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209\u2013219","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR41_6","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/A:1012244520615","volume":"18","author":"T Sakaeda","year":"2001","unstructured":"Sakaeda T, Nakamura T, Horinouchi M et al (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400\u20131404","journal-title":"Pharm Res"},{"key":"6_CR42_6","first-page":"1351","volume":"2","author":"S Taniguchi","year":"2003","unstructured":"Taniguchi S, Mochida Y, Uchiumi T et al (2003) Genetic polymorphism at the 5\u2032 regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2:1351\u20131359","journal-title":"Mol Cancer Ther"},{"key":"6_CR43_6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00008571-200208000-00005","volume":"12","author":"M Goto","year":"2002","unstructured":"Goto M, Masuda S, Saito H et al (2002) C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451\u2013457","journal-title":"Pharmacogenetics"},{"key":"6_CR44_6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00007691-200404000-00017","volume":"26","author":"M Eichelbaum","year":"2004","unstructured":"Eichelbaum M, Fromm MF, Schwab M (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26:180\u2013185","journal-title":"Ther Drug Monit"},{"key":"6_CR45_6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2133\/dmpk.20.391","volume":"20","author":"T Sakaeda","year":"2005","unstructured":"Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391\u2013414","journal-title":"Drug Metab Pharmacokinet"},{"key":"6_CR46_6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mcp.2002.129196","volume":"72","author":"A Johne","year":"2002","unstructured":"Johne A, Kopke K, Gerloff T et al (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584\u2013594","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR47_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","volume":"58","author":"C Verstuyft","year":"2003","unstructured":"Verstuyft C, Schwab M, Schaeffeler E et al (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809\u2013812","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR48_6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1046\/j.1365-2125.2002.01691.x","volume":"54","author":"T Gerloff","year":"2002","unstructured":"Gerloff T, Schaefer M, Johne A et al (2002) MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54:610\u2013616","journal-title":"Br J Clin Pharmacol"},{"key":"6_CR49_6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1023\/A:1023282312757","volume":"20","author":"Y Morita","year":"2003","unstructured":"Morita Y, Sakaeda T, Horinouchi M et al (2003) MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 20:552\u2013556","journal-title":"Pharm Res"},{"key":"6_CR50_6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1046\/j.1365-2125.2002.01591.x","volume":"53","author":"S Drescher","year":"2002","unstructured":"Drescher S, Schaeffeler E, Hitzl M et al (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526\u2013534","journal-title":"Br J Clin Pharmacol"},{"key":"6_CR51_6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clpt.2004.05.007","volume":"76","author":"SL Plasschaert","year":"2004","unstructured":"Plasschaert SL, Groninger E, Boezen M et al (2004) Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76:220\u2013229","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR52_6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood-2003-06-2105","volume":"103","author":"S Kishi","year":"2004","unstructured":"Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui CH, Relling MV (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67\u201372","journal-title":"Blood"},{"key":"6_CR53_6","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","volume":"112","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, Bouchet S, Turcq B et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024\u20132027","journal-title":"Blood"},{"key":"6_CR54_6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2125.2005.02392.x","volume":"60","author":"B Chowbay","year":"2005","unstructured":"Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159\u2013171","journal-title":"Br J Clin Pharmacol"},{"key":"6_CR55_6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1124\/dmd.32.2.168","volume":"32","author":"V Castagne","year":"2004","unstructured":"Castagne V, Bonhomme-Faivre L, Urien S et al (2004) Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Drug Metab Dispos 32:168\u2013171","journal-title":"Drug Metab Dispos"},{"key":"6_CR56_6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1023\/A:1020302825511","volume":"19","author":"T Sakaeda","year":"2002","unstructured":"Sakaeda T, Nakamura T, Hirai M et al (2002) MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 19:1323\u20131329","journal-title":"Pharm Res"},{"key":"6_CR57_6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1067\/mcp.2002.126706","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Altmannsberger S, Paneitz A et al (2002) Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther 72:256\u2013264","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR58_6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/07420520500180231","volume":"22","author":"H Ando","year":"2005","unstructured":"Ando H, Yanagihara H, Sugimoto K et al (2005) Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int 22:655\u2013665","journal-title":"Chronobiol Int"},{"key":"6_CR59_6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","volume":"50","author":"W Loscher","year":"2009","unstructured":"Loscher W, Klotz U, Zimprich F, Schmidt D (2009) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50:1\u201323","journal-title":"Epilepsia"},{"key":"6_CR60_6","first-page":"4955","volume":"62","author":"T Illmer","year":"2002","unstructured":"Illmer T, Schuler US, Thiede C et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955\u20134962","journal-title":"Cancer Res"},{"key":"6_CR61_6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1600-0609.2004.00228.x","volume":"72","author":"K Jamroziak","year":"2004","unstructured":"Jamroziak K, Mlynarski W, Balcerczak E et al (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72:314\u2013321","journal-title":"Eur J Haematol"},{"key":"6_CR62_6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/ijc.21666","volume":"118","author":"DH Kim","year":"2006","unstructured":"Kim DH, Park JY, Sohn SK et al (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195\u20132201","journal-title":"Int J Cancer"},{"key":"6_CR63_6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1532\/IJH97.E0418","volume":"81","author":"M Stanulla","year":"2005","unstructured":"Stanulla M, Schaffeler E, Arens S et al (2005) GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol 81:39\u201344","journal-title":"Int J Hematol"},{"key":"6_CR64_6","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1158\/1078-0432.CCR-07-1484","volume":"13","author":"CH Seedhouse","year":"2007","unstructured":"Seedhouse CH, Grundy M, White P et al (2007) Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res 13:7059\u20137066","journal-title":"Clin Cancer Res"},{"key":"6_CR65_6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clpt.2006.07.005","volume":"80","author":"B Holt van der","year":"2006","unstructured":"van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH et al (2006) ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80:427\u2013439","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR66_6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.leukres.2007.12.013","volume":"32","author":"EH Hur","year":"2008","unstructured":"Hur EH, Lee JH, Lee MJ et al (2008) C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res 32:1601\u20131604","journal-title":"Leuk Res"},{"key":"6_CR67_6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2007.12.009","volume":"32","author":"AF Semsei","year":"2008","unstructured":"Semsei AF, Erdelyi DJ, Ungvari I et al (2008) Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res 32:1214\u20131220","journal-title":"Leuk Res"},{"key":"6_CR68_6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2141.2007.06605.x","volume":"137","author":"G Buda","year":"2007","unstructured":"Buda G, Maggini V, Galimberti S et al (2007) MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 137:454\u2013456","journal-title":"Br J Haematol"},{"key":"6_CR69_6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1124\/jpet.108.138313","volume":"327","author":"Z Yang","year":"2008","unstructured":"Yang Z, Wu D, Bui T, Ho RJ (2008) A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 327:474\u2013481","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR70_6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00432-007-0279-9","volume":"134","author":"DT Petrova","year":"2008","unstructured":"Petrova DT, Nedeva P, Maslyankov S et al (2008) No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 134:317\u2013322","journal-title":"J Cancer Res Clin Oncol"},{"key":"6_CR71_6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/hmg\/ddi494","volume":"15","author":"GT Ho","year":"2006","unstructured":"Ho GT, Soranzo N, Nimmo ER et al (2006) ABCB1\/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15:797\u2013805","journal-title":"Hum Mol Genet"},{"key":"6_CR72_6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00228-005-0926-5","volume":"61","author":"M Kurzawski","year":"2005","unstructured":"Kurzawski M, Drozdzik M, Suchy J et al (2005) Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61:389\u2013394","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR73_6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00228-006-0225-9","volume":"63","author":"E Osswald","year":"2007","unstructured":"Osswald E, Johne A, Laschinski G et al (2007) Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 63:9\u201316","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR74_6","first-page":"1117","volume":"22","author":"A Kafka","year":"2003","unstructured":"Kafka A, Sauer G, Jaeger C et al (2003) Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117\u20131121","journal-title":"Int J Oncol"},{"key":"6_CR75_6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole SP, Bhardwaj G, Gerlach JH et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650\u20131654","journal-title":"Science"},{"key":"6_CR76_6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/01.fpc.0000167333.38528.ec","volume":"15","author":"G Conseil","year":"2005","unstructured":"Conseil G, Deeley RG, Cole SP (2005) Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 15:523\u2013533","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR77_6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00008571-200206000-00008","volume":"12","author":"S Conrad","year":"2002","unstructured":"Conrad S, Kauffmann HM, Ito K et al (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321\u2013330","journal-title":"Pharmacogenetics"},{"key":"6_CR78_6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00008571-200103000-00008","volume":"11","author":"S Ito","year":"2001","unstructured":"Ito S, Ieiri I, Tanabe M et al (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2\/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175\u2013184","journal-title":"Pharmacogenetics"},{"key":"6_CR79_6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/76102","volume":"25","author":"O Saux Le","year":"2000","unstructured":"Le Saux O, Urban Z, Tschuch C et al (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 25:223\u2013227","journal-title":"Nat Genet"},{"key":"6_CR80_6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1529-8817.2003.00124.x","volume":"68","author":"H Wang","year":"2004","unstructured":"Wang H, Hao B, Zhou K et al (2004) Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 68:563\u2013573","journal-title":"Ann Hum Genet"},{"key":"6_CR81_6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.fpc.0000173484.51807.48","volume":"15","author":"IJ Letourneau","year":"2005","unstructured":"Letourneau IJ, Deeley RG, Cole SP (2005) Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1\/ABCC1). Pharmacogenet Genomics 15:647\u2013657","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR82_6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/hmg\/ddi212","volume":"14","author":"Z Wang","year":"2005","unstructured":"Wang Z, Wang B, Tang K et al (2005) A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 14:2075\u20132087","journal-title":"Hum Mol Genet"},{"key":"6_CR83_6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/cncr.24042","volume":"115","author":"H Wang","year":"2009","unstructured":"Wang H, Jin G, Wang H et al (2009) Genetic susceptibility of lung cancer associated with common variants in the 3\u2032 untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer 115:595\u2013607","journal-title":"Cancer"},{"key":"6_CR84_6","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M et al (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754\u20133762","journal-title":"Circulation"},{"key":"6_CR85_6","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","volume":"25","author":"S Marsh","year":"2007","unstructured":"Marsh S, Paul J, King CR et al (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528\u20134535","journal-title":"J Clin Oncol"},{"key":"6_CR86_6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0005-2736(99)00169-8","volume":"1461","author":"J Konig","year":"1999","unstructured":"Konig J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377\u2013394","journal-title":"Biochim Biophys Acta"},{"key":"6_CR87_6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/A:1016020626941","volume":"18","author":"L Payen","year":"2002","unstructured":"Payen L, Sparfel L, Courtois A et al (2002) The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol 18:221\u2013233","journal-title":"Cell Biol Toxicol"},{"key":"6_CR88_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633\u2013671","journal-title":"Physiol Rev"},{"key":"6_CR89_6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1042\/BJ20051518","volume":"395","author":"V Vollrath","year":"2006","unstructured":"Vollrath V, Wielandt AM, Iruretagoyena M, Chianale J (2006) Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J 395:599\u2013609","journal-title":"Biochem J"},{"key":"6_CR90_6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/sj.tpj.6500403","volume":"7","author":"S Haenisch","year":"2007","unstructured":"Haenisch S, Zimmermann U, Dazert E et al (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56\u201365","journal-title":"Pharmacogenomics J"},{"key":"6_CR91_6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1124\/dmd.30.4.363","volume":"30","author":"M Itoda","year":"2002","unstructured":"Itoda M, Saito Y, Soyama A et al (2002) Polymorphisms in the ABCC2 (cMOAT\/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5\u2032-untranslated region and exon 28. Drug Metab Dispos 30:363\u2013364","journal-title":"Drug Metab Dispos"},{"key":"6_CR92_6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/FPC.0b013e3282f974b7","volume":"18","author":"S Haenisch","year":"2008","unstructured":"Haenisch S, May K, Wegner D et al (2008) Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 18:357\u2013365","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR93_6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","volume":"82","author":"M Naesens","year":"2006","unstructured":"Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074\u20131084","journal-title":"Transplantation"},{"key":"6_CR94_6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00228-007-0380-7","volume":"63","author":"M Miura","year":"2007","unstructured":"Miura M, Satoh S, Inoue K et al (2007) Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161\u20131169","journal-title":"Eur J Clin Pharmacol"},{"key":"6_CR95_6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.clpt.6100039","volume":"81","author":"L Renders","year":"2007","unstructured":"Renders L, Frisman M, Ufer M et al (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 81:228\u2013234","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR96_6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.fpc.0000236337.41799.b3","volume":"17","author":"JH Choi","year":"2007","unstructured":"Choi JH, Ahn BM, Yi J et al (2007) MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17:403\u2013415","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR97_6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","volume":"132","author":"AK Daly","year":"2007","unstructured":"Daly AK, Aithal GP, Leathart JB et al (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastro\u00adenterology 132:272\u2013281","journal-title":"Gastroenterology"},{"key":"6_CR98_6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/508546","volume":"194","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Hulot JS, Villard E et al (2006) Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194:1481\u20131491","journal-title":"J Infect Dis"},{"key":"6_CR99_6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1023\/B:PHAM.0000026422.06207.33","volume":"21","author":"M Hirouchi","year":"2004","unstructured":"Hirouchi M, Suzuki H, Itoda M et al (2004) Characterization of the cellular localization, expression level, and function of SNP variants of MRP2\/ABCC2. Pharm Res 21:742\u2013748","journal-title":"Pharm Res"},{"key":"6_CR100_6","first-page":"572","volume":"35","author":"P Ranganathan","year":"2008","unstructured":"Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572\u2013579","journal-title":"J Rheumatol"},{"key":"6_CR101_6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/01.fpc.0000230422.50962.91","volume":"16","author":"M Niemi","year":"2006","unstructured":"Niemi M, Arnold KA, Backman JT et al (2006) Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 16:801\u2013808","journal-title":"Pharmacogenet Genomics"},{"key":"6_CR102_6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.21214","volume":"44","author":"Y Meier","year":"2006","unstructured":"Meier Y, Pauli-Magnus C, Zanger UM et al (2006) Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62\u201374","journal-title":"Hepatology"},{"key":"6_CR103_6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhep.2007.08.015","volume":"48","author":"S Sookoian","year":"2008","unstructured":"Sookoian S, Castano G, Burgueno A, Gianotti TF, Pirola CJ (2008) Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 48:125\u2013132","journal-title":"J Hepatol"},{"key":"6_CR104_6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","volume":"80","author":"T Rau","year":"2006","unstructured":"Rau T, Erney B, Gores R et al (2006) High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 80:468\u2013476","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR105_6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/cncr.22760","volume":"110","author":"JY Han","year":"2007","unstructured":"Han JY, Lim HS, Yoo YK et al (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138\u2013147","journal-title":"Cancer"},{"key":"6_CR106_6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.clpt.6100019","volume":"81","author":"FA Jong de","year":"2007","unstructured":"de Jong FA, Scott-Horton TJ, Kroetz DL et al (2007) Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42\u201349","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR107_6","first-page":"5337","volume":"58","author":"R Allikmets","year":"1998","unstructured":"Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is invol\u00adved in multidrug resistance. Cancer Res 58:5337\u20135339","journal-title":"Cancer Res"},{"key":"6_CR108_6","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle LA, Yang W, Abruzzo LV et al (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665\u201315670","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR109_6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0167-4781(01)00270-6","volume":"1520","author":"KJ Bailey-Dell","year":"2001","unstructured":"Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520:234\u2013241","journal-title":"Biochim Biophys Acta"},{"key":"6_CR110_6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ijc.10100","volume":"97","author":"K Kage","year":"2002","unstructured":"Kage K, Tsukahara S, Sugiyama T et al (2002) Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S\u2013S dependent homodimerization. Int J Cancer 97:626\u2013630","journal-title":"Int J Cancer"},{"key":"6_CR111_6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s11095-005-6810-2","volume":"22","author":"K Ito","year":"2005","unstructured":"Ito K, Suzuki H, Horie T, Sugiyama Y (2005) Apical\/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22:1559\u20131577","journal-title":"Pharm Res"},{"key":"6_CR112_6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/dmd.105.007591","volume":"34","author":"HE Meyer Zu Schwabedissen","year":"2006","unstructured":"Meyer Zu Schwabedissen HE, Grube M, Dreisbach A et al (2006) Epidermal growth factor (EGF) mediated activation of the MAP kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34:524\u2013533","journal-title":"Drug Metab Dispos"},{"key":"6_CR113_6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2990.2005.00699.x","volume":"32","author":"SM Sisodiya","year":"2006","unstructured":"Sisodiya SM, Martinian L, Scheffer GL et al (2006) Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 32:51\u201363","journal-title":"Neuropathol Appl Neurobiol"},{"key":"6_CR114_6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.pharmtox.46.120604.141238","volume":"46","author":"P Krishnamurthy","year":"2006","unstructured":"Krishnamurthy P, Schuetz JD (2006) Role of ABCG2\/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381\u2013410","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6_CR115_6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1369\/jhc.5A6750.2005","volume":"54","author":"K Meissner","year":"2006","unstructured":"Meissner K, Heydrich B, Jedlitschky G et al (2006) The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem 54:215\u2013221","journal-title":"J Histochem Cytochem"},{"key":"6_CR116_6","doi-asserted-by":"publisher","first-page":"15649","DOI":"10.1073\/pnas.202607599","volume":"99","author":"JW Jonker","year":"2002","unstructured":"Jonker JW, Buitelaar M, Wagenaar E et al (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649\u201315654","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR117_6","first-page":"6635","volume":"61","author":"Y Honjo","year":"2001","unstructured":"Honjo Y, Hrycyna CA, Yan QW et al (2001) Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP-overexpressing cells. Cancer Res 61:6635\u20136639","journal-title":"Cancer Res"},{"key":"6_CR118_6","first-page":"611","volume":"1","author":"Y Imai","year":"2002","unstructured":"Imai Y, Nakane M, Kage K et al (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611\u2013616","journal-title":"Mol Cancer Ther"},{"key":"6_CR119_6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","volume":"56","author":"K Morisaki","year":"2005","unstructured":"Morisaki K, Robey RW, Ozvegy-Laczka C et al (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161\u2013172","journal-title":"Cancer Chemother Pharmacol"},{"key":"6_CR120_6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ijc.11669","volume":"109","author":"S Mizuarai","year":"2004","unstructured":"Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238\u2013246","journal-title":"Int J Cancer"},{"key":"6_CR121_6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","volume":"21","author":"C Kondo","year":"2004","unstructured":"Kondo C, Suzuki H, Itoda M et al (2004) Functional analysis of SNPs variants of BCRP\/ABCG2. Pharm Res 21:1895\u20131903","journal-title":"Pharm Res"},{"key":"6_CR122_6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00008571-200301000-00004","volume":"13","author":"CP Zamber","year":"2003","unstructured":"Zamber CP, Lamba JK, Yasuda K et al (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19\u201328","journal-title":"Pharmacogenetics"},{"key":"6_CR123_6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clpt.2004.03.003","volume":"76","author":"A Sparreboom","year":"2004","unstructured":"Sparreboom A, Gelderblom H, Marsh S et al (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76:38\u201344","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR124_6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","volume":"4","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Loos WJ, Burger H et al (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4:650\u2013658","journal-title":"Cancer Biol Ther"},{"key":"6_CR125_6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10637-006-6335-5","volume":"24","author":"WC Zamboni","year":"2006","unstructured":"Zamboni WC, Ramanathan RK, McLeod HL et al (2006) Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 24:393\u2013401","journal-title":"Invest New Drugs"},{"key":"6_CR126_6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.toxlet.2005.10.015","volume":"162","author":"I Cascorbi","year":"2006","unstructured":"Cascorbi I (2006) Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 162:16\u201328","journal-title":"Toxicol Lett"},{"key":"6_CR127_6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","volume":"25","author":"M Ingelman-Sundberg","year":"2004","unstructured":"Ingelman-Sundberg M (2004) Pharmaco\u00adgenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193\u2013200","journal-title":"Trends Pharmacol Sci"},{"key":"6_CR128_6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361\u2013398","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6_CR129_6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/gut.52.12.1788","volume":"52","author":"CG Dietrich","year":"2003","unstructured":"Dietrich CG, Geier A, Oude Elferink RP (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52:1788\u20131795","journal-title":"Gut"},{"key":"6_CR130_6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260\u2013277","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR131_6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1517\/14656566.6.14.2455","volume":"6","author":"A Sakurai","year":"2005","unstructured":"Sakurai A, Tamura A, Onishi Y, Ishikawa T (2005) Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 6:2455\u20132473","journal-title":"Expert Opin Pharmacother"},{"key":"6_CR132_6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.febslet.2004.03.123","volume":"567","author":"B Sarkadi","year":"2004","unstructured":"Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004) ABCG2 \u2013 a transporter for all seasons. FEBS Lett 567:116\u2013120","journal-title":"FEBS Lett"},{"key":"6_CR133_6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0169-409X(02)00075-3","volume":"54","author":"H Suzuki","year":"2002","unstructured":"Suzuki H, Sugiyama Y (2002) Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2\/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 54:1311\u20131331","journal-title":"Adv Drug Deliv Rev"},{"key":"6_CR134_6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pharmthera.2006.04.009","volume":"112","author":"I Cascorbi","year":"2006","unstructured":"Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457\u2013473","journal-title":"Pharmacol Ther"},{"key":"6_CR135_6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/mol.62.1.1","volume":"62","author":"C Kimchi-Sarfaty","year":"2002","unstructured":"Kimchi-Sarfaty C, Gribar JJ, Gottesman MM (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 62:1\u20136","journal-title":"Mol Pharmacol"},{"key":"6_CR136_6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1248\/bpb.25.1356","volume":"25","author":"Y Moriya","year":"2002","unstructured":"Moriya Y, Nakamura T, Horinouchi M et al (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356\u20131359","journal-title":"Biol Pharm Bull"},{"key":"6_CR137_6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T et al (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94\u2013101","journal-title":"Drug Metab Dispos"}],"container-title":["Methods in Molecular Biology","Multi-Drug Resistance in Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-60761-416-6_6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:53:57Z","timestamp":1739408037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-60761-416-6_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,5]]},"ISBN":["9781607614159","9781607614166"],"references-count":137,"URL":"https:\/\/doi.org\/10.1007\/978-1-60761-416-6_6","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-60761-416-6","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,5]]}}}